Company intelligence
Lexicon Pharmaceuticals, Inc.
At Lexicon, We Pioneer Medicines that Transform Patients' Lives
About Lexicon Pharmaceuticals, Inc.
Corporate Overview Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. The Genome: Our Source of Discovery We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. A Diverse Pipeline of Targeted Therapies Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.
Verified activity
Signals from Lexicon Pharmaceuticals, Inc.
2 published signals
Presence & Recognition
Lexicon Pharmaceuticals, Inc. announced that the upcoming Congressional Briefing titled Advancing Chronic Pain Initiatives: Policy Priorities That Reach Patients will be held on Wednesday, September 9, at 12:00 PM to 1:00 PM ET at SVC 201-00, U.S. Capitol Visitor Center.
Reported by Lexicon Pharmaceuticals, Inc.
Presence & Recognition
Lexicon Pharmaceuticals, Inc. is participating in three upcoming investor conferences in New York this month.
Reported by Lexicon Pharmaceuticals, Inc.